Product Description
TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression.
Mechanisms of Action: MGLUR2/3 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Taisho R&D
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
000101-M | P2 |
Completed |
Depressive Disorder, Major|Depressive Disorder, Treatment-Resistant |
2024-05-23 |